| scholarly article | Q13442814 |
| P50 | author | Karen Ashe | Q6369493 |
| Sylvain Lesné | Q57587621 | ||
| P2093 | author name string | Dominic M Walsh | |
| Mary Jo LaDu | |||
| Chunjiang Yu | |||
| Lisa Jungbauer | |||
| Miranda N Reed | |||
| James P Cleary | |||
| Alfred T Welzel | |||
| Mathew A Sherman | |||
| Jacki J Hofmeister | |||
| P2860 | cites work | Utilization of a novel model of food reinforced behavior involving neuropeptide Y, insulin, 2-deoxy-d-glucose and naloxone | Q73554153 |
| The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain | Q74290658 | ||
| Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as | Q79851539 | ||
| Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice | Q22242267 | ||
| Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory | Q24645499 | ||
| Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo | Q28131779 | ||
| Evidence that production and release of amyloid beta-protein involves the endocytic pathway | Q28244336 | ||
| A specific amyloid-beta protein assembly in the brain impairs memory | Q28854597 | ||
| Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins | Q29547593 | ||
| Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function | Q29614851 | ||
| A beta oligomers - a decade of discovery | Q29615152 | ||
| Solution state characterization of amyloid beta-derived diffusible ligands | Q33266914 | ||
| In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis | Q34166792 | ||
| Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging | Q35754595 | ||
| The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. | Q36295340 | ||
| Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation | Q37119890 | ||
| Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay | Q40404080 | ||
| Amyloid-beta1-42 reduces neuronal excitability in mouse dentate gyrus | Q42568400 | ||
| Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture | Q42805272 | ||
| Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta(1-42) injections in the rat. | Q44189359 | ||
| Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers | Q48326021 | ||
| Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein | Q48342880 | ||
| Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers | Q48654859 | ||
| Neurotoxic protein oligomers--what you see is not always what you get. | Q48708958 | ||
| ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42. | Q49149877 | ||
| Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. | Q53248798 | ||
| P433 | issue | 10 | |
| P304 | page(s) | 1784-1794 | |
| P577 | publication date | 2010-01-19 | |
| P1433 | published in | Neurobiology of Aging | Q7002141 |
| P1476 | title | Cognitive effects of cell-derived and synthetically derived Aβ oligomers | |
| P478 | volume | 32 |
| Q90375051 | A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer's brain |
| Q90628076 | A novel crosslinking protocol stabilizes amyloid β oligomers capable of inducing Alzheimer's-associated pathologies |
| Q27010785 | A window into the heterogeneity of human cerebrospinal fluid Aβ peptides |
| Q89861110 | APP Osaka Mutation in Familial Alzheimer's Disease-Its Discovery, Phenotypes, and Mechanism of Recessive Inheritance |
| Q91710120 | Acute Pannexin 1 Blockade Mitigates Early Synaptic Plasticity Defects in a Mouse Model of Alzheimer's Disease |
| Q30535426 | Alzheimer brain-derived amyloid β-protein impairs synaptic remodeling and memory consolidation |
| Q38026984 | Alzheimer's disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory. |
| Q37636545 | Alzheimer's disease: synaptic dysfunction and Abeta |
| Q28544876 | Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits |
| Q47113449 | Amino-Terminal β-Amyloid Antibody Blocks β-Amyloid-Mediated Inhibition of the High-Affinity Choline Transporter CHT. |
| Q47990795 | Amyloid Beta monomers regulate cyclic adenosine monophosphate response element binding protein functions by activating type-1 insulin-like growth factor receptors in neuronal cells |
| Q34567280 | Amyloid beta dimers/trimers potently induce cofilin-actin rods that are inhibited by maintaining cofilin-phosphorylation |
| Q35533112 | Amyloid β-mediated Zn2+ influx into dentate granule cells transiently induces a short-term cognitive deficit |
| Q37690332 | Amyloid β-protein oligomers and Alzheimer's disease |
| Q46625235 | Amyloid-β dimers in the absence of plaque pathology impair learning and synaptic plasticity. |
| Q37361564 | Amyloid-β oligomers regulate the properties of human neural stem cells through GSK-3β signaling |
| Q37286244 | Assessing the Effects of Acute Amyloid β Oligomer Exposure in the Rat. |
| Q56342045 | Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons |
| Q30539133 | Brain amyloid-β oligomers in ageing and Alzheimer's disease |
| Q26862630 | Breaking the Code of Amyloid-β Oligomers |
| Q39330851 | Clustering of sialylated glycosylphosphatidylinositol anchors mediates PrP-induced activation of cytoplasmic phospholipase A 2 and synapse damage |
| Q37051726 | Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults |
| Q35191297 | Di-tyrosine cross-link decreases the collisional cross-section of aβ peptide dimers and trimers in the gas phase: an ion mobility study |
| Q35013344 | Elucidating molecular mass and shape of a neurotoxic Aβ oligomer. |
| Q40893495 | Endocytic pathways mediating oligomeric Abeta42 neurotoxicity. |
| Q92070015 | Functional Amyloids and their Possible Influence on Alzheimer Disease |
| Q36605311 | Glycogen synthase kinase-3 inhibition prevents learning deficits in diabetic mice |
| Q37295754 | High-molecular weight Aβ oligomers and protofibrils are the predominant Aβ species in the native soluble protein fraction of the AD brain |
| Q35813445 | High-resolution NMR characterization of low abundance oligomers of amyloid-β without purification |
| Q27497796 | IVIg protects the 3xTg-AD mouse model of Alzheimer’s disease from memory deficit and Aβ pathology |
| Q48113629 | Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology model. |
| Q35646336 | Involvement of Intracellular and Mitochondrial Aβ in the Ameliorative Effects of Huperzine A against Oligomeric Aβ42-Induced Injury in Primary Rat Neurons |
| Q38121070 | Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review. |
| Q38543419 | Lipids in Amyloid-β Processing, Aggregation, and Toxicity |
| Q46518657 | Memantine rescues transient cognitive impairment caused by high-molecular-weight aβ oligomers but not the persistent impairment induced by low-molecular-weight oligomers. |
| Q36666929 | Mesenchymal Stem Cells Preserve Working Memory in the 3xTg-AD Mouse Model of Alzheimer's Disease |
| Q36824513 | Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer's disease |
| Q35925948 | Monomeric ß-amyloid interacts with type-1 insulin-like growth factor receptors to provide energy supply to neurons |
| Q34125360 | Natural amyloid-β oligomers acutely impair the formation of a contextual fear memory in mice |
| Q38619618 | Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease. |
| Q46814312 | Novel 5-aryloxypyrimidine SEN1576 as a candidate for the treatment of Alzheimer's disease |
| Q38794219 | Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases. |
| Q42021752 | Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? |
| Q36187149 | Postsynaptic dysfunction is associated with spatial and object recognition memory loss in a natural model of Alzheimer's disease |
| Q37729219 | Potential Neuroprotective Effects of Adiponectin in Alzheimer's Disease |
| Q35826425 | Quaternary Structure Defines a Large Class of Amyloid-β Oligomers Neutralized by Sequestration |
| Q46943581 | Republished: the role of amyloid β in the pathogenesis of Alzheimer's disease |
| Q35663419 | Soluble Aβ oligomer production and toxicity |
| Q35643397 | Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease |
| Q52568535 | Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. |
| Q38549882 | Structural, morphological, and functional diversity of amyloid oligomers |
| Q41894180 | Structure-activity relationships in peptide modulators of β-amyloid protein aggregation: variation in α,α-disubstitution results in altered aggregate size and morphology |
| Q41896658 | Structure-dependent effects of amyloid-β on long-term memory in Lymnaea stagnalis |
| Q45991189 | Surprising toxicity and assembly behaviour of amyloid β-protein oxidized to sulfone. |
| Q27320084 | Tailoring the antibody response to aggregated Aß using novel Alzheimer-vaccines |
| Q26822002 | Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics |
| Q34792043 | Targets for AD treatment: conflicting messages from γ-secretase inhibitors |
| Q48262149 | Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model. |
| Q34720146 | Telencephalin protects PAJU cells from amyloid beta protein-induced apoptosis by activating the ezrin/radixin/moesin protein family/phosphatidylinositol-3-kinase/protein kinase B pathway |
| Q54977832 | The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. |
| Q46368794 | The amyloid-β oligomer Aβ*56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation. |
| Q37774042 | The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? |
| Q34054680 | The intersection of amyloid beta and tau at synapses in Alzheimer's disease |
| Q36719033 | The neurodegeneration in Alzheimer disease and the prion protein |
| Q37979641 | The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes |
| Q34317403 | Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5). |
| Q38265644 | Toxic oligomer species of amyloid-β in Alzheimer's disease, a timing issue. |
| Q38275791 | Viral capsid assembly as a model for protein aggregation diseases: Active processes catalyzed by cellular assembly machines comprising novel drug targets |
| Q36981528 | β-Amyloid oligomers in aging and Alzheimer's disease |
Search more.